argenx SE announced that the U.S. Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for VYVGART Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy.
argenx SE announced that the U.S. Food and Drug Administration has accepted for priority review a supplemental Biologics License Application for VYVGART Hytrulo for the treatment of chronic inflammatory demyelinating polyneuropathy.